scholarly journals The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer

2016 ◽  
Vol 12 (5) ◽  
pp. 3449-3456 ◽  
Author(s):  
Christian Ostheimer ◽  
Franziska Schweyer ◽  
Thomas Reese ◽  
Matthias Bache ◽  
Dirk Vordermark
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Volume ◽  
Small Cell ◽  
Radical Radiotherapy ◽  
Small Cell Lung ◽  
Volume Changes ◽  
The Relationship

scholarly journals Tumor volume shrinkage during stereotactic body radiotherapy is related to better prognoses in patients with stage I non-small-cell lung cancer

2020 ◽  
Vol 61 (5) ◽  
pp. 740-746
Author(s):  
Nam Vu ◽  
Hiroshi Onishi ◽  
Masahide Saito ◽  
Kengo Kuriyama ◽  
Takafumi Komiyama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Local Control ◽  
Cell Lung Cancer ◽  
Tumor Volume ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Volume Changes

Abstract The purpose of the study was to investigate the association between tumor volume changes during stereotactic body radiation therapy (SBRT) and prognoses in stage I non-small-cell lung cancer (NSCLC). This retrospective review included stage I NSCLC patients in whom SBRT was performed at a total dose of 48.0–50.5 Gy in four or five fractions. The tumor volumes observed on computed tomography (CT) simulation and on the CT performed at the last treatment session using a CT-on-rails system were measured and compared. Then, the tumor volume changes during the SBRT period were measured and assessed for their association with prognoses (overall survival, local control, lymph node metastases and distant metastases). A total of 98 patients with a mean age of 78.6 years were enrolled in the study. The T-stage was T1a in 42%, T1b in 32% and T2a in 26% of the cases. The gross tumor volume (GTV) shrank and increased ≥10% in 23 (23.5%) and 36 (36.7%) of the cases, respectively. The 5-year local control and overall survival rates in the groups with a tumor shrinkage of ≥10% vs the group with a shrinkage of <10% were 94.7 vs 70.8% and 85.4 vs 47.6%, respectively; these differences were significant, with a P-value < 0.05. During a short SBRT period, the tumor shrank or enlarged in a small number of cases. A decrease of ≥10% in the GTV during SBRT was significantly related to better overall survival and local control.

Tumor volume changes on serial imaging with megavoltage CT for non-small cell lung cancer during conformal radiotherapy

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17041-17041
Author(s):  
M. L. Siker ◽  
W. A. Tome ◽  
M. P. Mehta
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Volume ◽  
Tumor Regression ◽  
Small Cell ◽  
Small Cell Lung ◽  
Volume Changes ◽  
Megavoltage Ct ◽  
Plan Modification

17041 Background: Adaptive radiotherapy allows treatment plan modification based on data obtained during treatment. Assessing volume changes during treatment is now possible with intra-treatment imaging capabilities on radiotherapy devices. This study assesses non-small cell lung cancer (NSCLC) volume changes during treatment with conformal intensity-modulated radiotherapy by evaluating serial megavoltage CT (MVCT) scans. Methods: MVCTs were retrospectively reviewed for 25 patients treated with the TomoTherapy Hi-Art system at the University of Wisconsin. Twenty-one patients received definitive radiotherapy, 4 with extracranial stereotactic radioablation (60 Gy in 5 fractions) and 17 on a dose-per-fraction escalation protocol (57–80.5 Gy in 25 fractions). Four patients were treated palliatively (22–30 Gy in 8–10 fractions). Gross tumor volumes (GTVs) were contoured on serial MVCTs at weekly intervals, by individuals other than the treating physician, to minimize bias. Each patient had 3–25 scans including one at the beginning, mid-way, and one at the end of treatment. Initial GTVs ranged from 1.4 - 565.5 cm3 (mean = 70 cm3). Results: At completion of treatment, no patient demonstrated a complete response (CR). Partial response (PR) defined as a >65% decrease in tumor volume occurred in 3 (12%) and marginal response (MR) defined as a 35 - 65% reduction in tumor volume was noted in 5 (20%). The remaining 17 patients (68%) showed stable disease (SD) defined as <35% reduction or <40% increase in size. The minimum “scorable threshold” for volume discrepancy between scans to account for inter-scan assessment variability was set at >25% volume change; 10 patients (40%) had >25% tumor regression. None of the patients treated ablatively or palliatively showed tumor regression during treatment. Conclusions: Although gross tumor regression during treatment may be objectively measured using MVCTs, substantial volumetric decrease occurs only in a minority. The clinical significance of this regression is questionable, as there is no way to document histologic tumor clearance and therefore field reductions during radiotherapy cannot be recommended. [Table: see text]

Quantification of Tumor Volume Changes During Radiotherapy for Non–Small-Cell Lung Cancer

2009 ◽  
Vol 74 (2) ◽  
pp. 341-348 ◽  
Author(s):  
Jana Fox ◽  
Eric Ford ◽  
Kristin Redmond ◽  
Jessica Zhou ◽  
John Wong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Volume ◽  
Small Cell ◽  
Small Cell Lung ◽  
Volume Changes
Sign in / Sign up

Export Citation Format

Share Document